Expression of MSP58 in human colorectal cancer and its correlation with prognosis

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3136-3142

  Shi, Hai ^a   Li, Shu Jun ^a   Zhang, Bo ^b   Liu, He Liang ^a   Chen, Chang Sheng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Immunohistochemistry; MSP58; Prognosis; UICC

Indexed keywords

58 KDA MICRO SPHERULE PROTEIN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; MCRS1 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; AREA UNDER THE CURVE; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA-BINDING PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880276140     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0284-y     Document Type: Article

References (34)

1. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-60.
2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78.
3. Punt CJ, Tol J. More is less - combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol. 2009;6(12):731-3.
4. Obeidat NA, Pradel FG, Zuckerman IH, DeLisle S, Mullins CD. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother. 2009;7(6):343-54.
5. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308-24.
6. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489-99.
7. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67-81.
8. Ren Y, Busch RK, Perlaky L, Busch H. The 58-kDa microspherule protein (MSP58), a nucleolar protein, interacts with nucleolar protein p120. Eur J Biochem. 1998;253(3):734-42.
9. Lin DY, Shih HM. Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration. J Biol Chem. 2002;277(28):25446-56.
10. Ivanova AV, Ivanov SV, Lerman ML. Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. Cell Mol Life Sci. 2005;62(4):471-84.
11. Bader AG, Schneider ML, Bister K, Hartl M. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene. 2001;20(51):7524-35.
12. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A. 2005;102(8):2703-6.
13. Zhang J, Liu J, Li X, Li F, Wang L, Zhang J, Liu X, Shen L, Liu N, Deng Y, Yang A, Han H, Zhao M, Yao L. The physical and functional interaction of NDRG2 with MSP58 in cells. Biochem Biophys Res Commun. 2007;352(1):6-11.
14. Lin W, Zhang J, Zhang J, Liu X, Fei Z, Li X, Davidovic L, Tang Z, Shen L, Deng Y, Yang A, Han H, Zhang X, Yao L. RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line. J Cell Mol Med. 2009;13(11-12):4608-22.
15. Shi H, Chen S, Jin H, Xu C, Dong G, Zhao Q, Wang W, Zhang H, Lin W, Zhang J, Davidovic L, Yao L, Fan D. Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway. Cancer Sci. 2009;100(9):1585-90.
16. Davidovic L, Bechara E, Gravel M, Jaglin XH, Tremblay S, Sik A, Bardoni B, Khandjian EW. The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol Genet. 2006;15(9):1525-38.
17. Shi H, Zhou Y, Liu H, Chen C, Li S, Li N, Li X, Zhang X, Zhang H, Wang W, Zhao Q. Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis. BMC Cancer. 2010;10:477.
18. Shi H, Li N, Li S, Chen C, Wang W, Xu C, Zhang J, Jin H, Zhang H, Zhao H, Song W, Feng Q, Feng X, Shen X, Yao L, Zhao Q. Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci. 2010;101(5):1292-9.
19. Li S, Shi H, Ji F, Wang B, Feng Q, Feng X, Jia Z, Zhao Q, Qian G. The human lung cancer drug resistance-related gene BC006151 regulates chemosensitivity in H446/CDDP cells. Biol Pharm Bull. 2010;33(8):1285-90.
20. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-6.
21. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2005;55:74-108.
22. Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res. 2006;12:6985-8.
23. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics. CA Cancer J Clin. 2004;54:8-29.
24. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104:57-64.
25. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044-8.
26. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-8.
27. Du X, Wang Q, Hirohashi Y, Greene MI. DIPA, which can localize to the centrosome, associates with p78/MCRS1/MSP58 and acts as a repressor of gene transcription. Exp Mol Pathol. 2006;81(3):184-90.
28. Andersen DS, Raja SJ, Colombani J, Shaw RL, Langton PF, Akhtar A, Tapon N. Drosophila MCRS2 associates with RNA polymerase II complexes to regulate transcription. Mol Cell Biol. 2010;30(19):4744-55.
29. Shimono K, Shimono Y, Shimokata K, Ishiguro N, Takahashi M. Microspherule protein 1, Mi-2beta, and RET finger protein associate in the nucleolus and up-regulate ribosomal gene transcription. J Biol Chem. 2005;280(47):39436-47.
30. Song H, Li Y, Chen G, Xing Z, Zhao J, Yokoyama KK, Li T, Zhao M. Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1 and reduces the telomere length. Biochem Biophys Res Commun. 2004;316(4):1116-23.
31. Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH, Yang Y, Lim JS, Lee HG. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39(6):705-14.
32. Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C, Xu C, Fan D, Yao L. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull. 2009;32(6):968-75.
33. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, Kim JW, Song EY, Kim DM, Lee MN, Oh GT, Kim SJ, Park KC, Yoo HS, Choi JY, Yeom YI. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res. 2008;68(11):4210-20.
34. Zhao H, Zhang J, Lu J, He X, Chen C, Li X, Gong L, Bao G, Fu Q, Chen S, Lin W, Shi H, Ma J, Liu X, Ma Q, Yao L. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer. 2008;8:303.